Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android. Learn more here!

General Principles in Older Adults

Persons 65 years or older comprise approximately 13% of the U.S. population, yet they are prescribed the greatest proportion of medication; 90% are prescribed at least 1 prescription drug and 65% 3 or more prescription drugs in the last month. They also represent the fastest growing segment of prescription drug users in the United States. Thus, with an increasing number of patients surviving to older age and consuming larger amounts of drugs, it is necessary for clinicians to understand the risk, benefits, and consequences of drug therapy in older patients. This is especially true for anticoagulants, a class of drugs essential for the optimal management of many thromboembolic and vascular disorders that are highly prevalent among older patients. Anticoagulants are unique compared to most pharmacologic agents because even small deviations from “therapeutic levels” place patients at risk for life-threatening complications. While older patients with multimorbidity are particularly susceptible to thrombosis, they also have higher risks of bleeding than the general population. This chapter briefly reviews current anticoagulant therapy and focuses on the newer agents and recommendations for their use in older patients.

Health, United States, 2012, with Special Feature on Emergency Care. United States Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, May 2013, DHHS Publication No. 2013-1232 Table 1, Page 45, and Table 9, page 282 at (last accessed December 6, 2013).

Available Classes of Anticoagulant Therapy

Current anticoagulants that are available for use within the United States include unfractionated heparin (UFH), vitamin K antagonists (VKAs), low-molecular weight heparins (LMWHs), indirect selective factor Xa inhibitor, and the direct thrombin (parental and oral) and factor Xa inhibitors. Tables 55–1 and 55–2 summarize the specific pharmacologic characteristics of these agents.

Table 55–1.Pharmacologic properties of parental anticoagulants.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.